Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

The iShares Core MSCI EAFE ETF (IEFA) is highlighted as one of the best international ETFs, offering diversified exposure to over 2,600 stocks across 16+ developed markets with a low 0.07% expense ratio and 3.30% dividend yield. While it has underperformed the S&P 500 recently, the fund provides valuable portfolio diversification and could serve as a hedge against U.S. market volatility, particularly if tech stocks decline from current valuations.

IEFA: Why This Fund Is One of the Best International ETFs

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

CRISPR Therapeutics acquired CTX611, a clinical-stage siRNA therapy targeting Factor XI for blood clot prevention, for $95 million upfront. The program could significantly impact the company's revenue despite being a follower in a competitive anticoagulant market dominated by Eliquis and other therapies. With only $1.4 million in Q1 2026 revenue, success with CTX611 could be transformative for the stock.

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

Novartis announced that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) demonstrated consistent radiographic progression-free survival improvements across key patient subgroups when combined with standard of care in PSMA-positive metastatic hormone-sensitive prostate cancer. The PSMAddition trial showed a 28% reduction in radiographic progression or death risk. Regulatory submissions have been filed in the US, China, and Japan with decisions expected in H2 2026. Additionally, Novartis presented promising Phase 1 data for its actinium-based radioligand therapy 225Ac-PSMA-617, with two Phase 3 trials underway.

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Novartis AG ADR (NVS) Stock Price, Analysis & Trade Signals